Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Thorough QT/QTc Study of Multiple Oral Doses of NOMAC-E2 (Org 10486 0 + Org 2317) in Healthy Women (Study 292011)(P05802)
Phase 1
Completed
- Conditions
- Contraception
- Interventions
- Drug: NOMAC-E2 (Org 10486-0 + Org 2317)Drug: NOMAC-E2 placebo
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 189
- Registration Number
- NCT00779532
Equivalency Study of Two Formulations of Mometasone Furoate Nasal Spray (Study P04419)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 102
- Registration Number
- NCT00779740
Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 506
- Registration Number
- NCT00779636
Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 217
- Registration Number
- NCT00779116
MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 120
- Registration Number
- NCT00771160
Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 367
- Registration Number
- NCT00764478
Elocon vs Fluticasone in Localized Psoriasis (P03197)
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 245
- Registration Number
- NCT00763529
Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)
Completed
- Conditions
- Rhinitis, Allergic, SeasonalRhinitis, Allergic, PerennialUrticaria
- Interventions
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2980
- Registration Number
- NCT00761527
Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 500
- Registration Number
- NCT00757627
Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)
Phase 3
Completed
- Conditions
- Chronic Idiopathic UrticariaAtopy
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 97
- Registration Number
- NCT00757562